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Neutralization of streptokinase by an unsuspected high
titer of antistreptokinase antibody prevented activation
of the fibrinolytic system and induction of a lytic state
in a 62 year old man with an acute inferior myocardial
infarction. There was no decrease in serum fibrinogen,
minimal decrease in serum plasminogen and only a small
increase in serum fibrin degradation products after in-
Administration of streptokinase results in thrombolysis and
reperfusion of the occluded infarct artery in a high propor-
tion of patients with an evolving myocardial infarction (1-5).
Streptokinase is a polypeptide produced by beta-hemolytic
streptococcal bacteria that acts as an exogenous indirect
activator of the human fibrinolytic system (6). Streptokinase
binds to circulating plasminogen, forming a plasminogen-
activator complex that generates the proteolytic enzyme
plasmin from uncomplexed plasminogen (7). Thrombus-
bound plasmin hydrolyzes fibrin resulting in thrombolysis,
while circulating plasmin hydrolyzes circulating fibrinogen
(8,9).
Antistreptokinase antibodies bind and inactivate strep-
tokinase (10). Although low titers of antistreptokinase an-
tibody are ubiquitous in human subjects due to past strep-
tococcal exposure, several investigators (11,12) have
demonstrated that antistreptokinase antibodies are neutral-
ized by less than 250,000 IV of streptokinase in more than
90% of the population. Current dosage regimens allow for
neutralization of these antibodies by a portion of the strep-
tokinase administered, while leaving most of the strepto-
kinase free to complex with plasminogen and initiate throm-
bolysis (12-13). A high titer of antistreptokinase antibody
is produced in response to streptokinase administration and
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travenous administration of 1.5 million units of strep-
tokinase. A high titer of antistreptokinase antibody, suf-
ficient to neutralize 1.5 million units of streptokinase,
was demonstrated by semiquantitative counterelectro-
phoresis. There was no clinical evidence of coronary
artery reperfusion, and coronary angiography con-
firmed complete occlusion of the left circumflex artery.
acutely after streptococcal infection (6,14). In the presence
of a high titer of antibody, the usual dose of streptokinase
may be ineffective, fail to activate the fibrinolytic system
and, therefore, fail to effect thrombolysis.
We report a case of acute myocardial infarction in which
1.5 million units of streptokinase failed to activate the fi-
brinolytic system because of an unsuspected high titer of
circulating antistreptokinase antibodies.
Case Report
A 62 year old white man was admitted with an acute
inferior myocardial infarction after 2 weeks of effort angina.
He had a 2 year history of diabetes mellitus of mature onset,
had stopped smoking I year before this admission and had
recently been in good health. There was no history of recent
infection and he had not previously received streptokinase.
On the morning of admission, he had experienced a sud-
den onset of severe retrosternal chest pain, nausea and dia-
phoresis at home. He was attended by paramedical officers
who noted the onset of atrial fibrillation. On arrival in the
emergency room, he was pale and diaphoretic with an ir-
regular pulse at a rate of 50 to 70 beats/min and a blood
pressure of 100170 mm Hg. There were no signs of left or
right heart failure. The remainder of the examination was
noncontributory .
The electrocardiogram demonstrated atrial fibrillation and
changes of acute inferoposterior myocardial infarction with
2 mm of ST segment elevation in leads II, III and aVF and
I to 2 mm ST segment depression in the precordial leads
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Laboratory investigation revealed a normal blood urea
nitrogen, electrolytes and complete blood count. The white
cell count was 11.0 x 103 per mrrr' with a normal differ-
ential. Plasma glucose was 316 mg/IOO ml and the serum
creatine kinase level was not elevated at 47 IU/liter with an
MB fraction of 1.8 ill/liter. Serum fibrinogenwas 260 mg/100
ml and serum plasminogen was 9.6 mgllOO ml (normal
value 10 to 20 mglloo ml).
Informed consent was obtained from the patient to be
treated with intravenous streptokinase infusion according to
our current research protocol. Hydrocortisone, 100 mg, was
administered intravenously, followed by a 15 minute intra-
venous infusion of 750,000 IU of streptokinase, commenc-
ing 2 hours and 15 minutes after the onset of chest pain.
Ninety minutes after the streptokinase infusion, there were
no clinical signs of coronary artery reperfusion. A second
intravenous infusion of 750,000 IU of streptokinase also
failed to produce signs of reperfusion . Full anticoagulation
was commenced with intravenous heparin .
Serial electrocardiography performed over 24 hours
demonstrated evolution of an inferoposterior myocardial in-
farction with new Q waves and loss of R waves in leads II,
Ill and aYF and a new primary R wave in lead YI' Serum
total creatine kinase and MB fraction peaked at 1,019 and
97 Il.l/Iiter, respectively, 22 hours after the onset of chest
pain .
Coronary angiography on the fifth hospital day dem-
onstrated complete occlusion of the left circumflex coronary
artery and three vessel coronary artery disease . The clinical
course was complicated by pericarditis and moderate pul-
monary congestion.
Demonstration of antistreptokinse antibodies. Serum
fibrinogen was 285 and 280 mgllOO ml at 90 minutes and
4 hours, respectively, after completion of the first and sec-
ond infusions of streptokinase. Serum plasminogen was 7.8
and 7.2 mgt I00 ml at 35 minutes after each of the two
infusions, respectively. Fibrin degradation products were
slightly elevated at 30 JLg/ml, 3 hours after 1.5 million IU
of streptokinase (normal value < 10 JLg/ml). In this patient,
neither serum fibrinongen nor serum plasminogen levels
decreased after two intravenous infusions of 750,000 IU of
streptokinase. This raised the suspicion that the drug either
was ineffective or had been inactivated subsequent to admin-
istration. Because streptokinase from the same batch had
previously proved effective in nine patients , we concluded
that a serum streptokinase inhibitor had inactivated strep-
tokinase before its complexing with plasminogen. The pres-
ence of a positive antistreptolysin a screen prompted the
search for neutralizing antistreptokinase antibodies .
Antistreptokinase antibodies were demonstrated by counter-
electrophoresis, using a modification of the semiquantitative
technique described by Spottl and Kaiser (15). Counterelec-
trophoresis was performed on 1% agarose plates (32 mm
x 100 mm x 2 mm) using an electrophoresis chamber and
power source. Agarose (Bio-Rad Laboratories, High-Mj)
dissolved in Tris , Barbital Sodium Barbital buffer at pH 8.8
was used. Two rows of identical wells , each containing
approximately 10 ml, were cut into the agarose plate . The
cathodic wells were filled with streptokinase (Hoechst-
Roussel) at a concentration of 2,500 IU/ml and the anodic
wells were filled with serum to be tested for antistreptokinase
antibodies. After a 25 minute run at 25 rnA, the plates were
incubated at room temperature in a moist chamber for 24
hours . A precipitant line between the rows of wells indicated
the presence of streptokinase antibody in the serum .
The specificity of this technique was established by test-
ing for antistreptokinase antibodies in pooled negative serum,
pooled negative plasma, pretreatment sera of 12 patients
who underwent successful streptokinase thrombolysis and
the pretreatment serum of 1 patient in whom streptokinase
thrombolysis failed despite activation of the fibrinolytic sys-
tem . No precipitant line was formed with any of these sera.
The sensitivity of the technique was established by dem-
onstration of a precipitant line in all five patients whose
serum was also tested 14 days after successful streptokinase
therapy , the time when a high titer of antistreptokinase an-
tibody is expected.
Semiquantitative gel counterelectrophoresis confirmed the
presence of a high titer of antistreptokinase antibody in both
the pre- and posttreatment sera of our patient. A precipitant
line was formed up to a dilution of I in 4 with pretreatment
serum and up to a I in 16 dilution with posttreatment serum .
Spottl and Kaiser (15) found a good correlation between
their semiquantitative and quantitative techniques. Accord-
ing to their report (15), the formation of a precipitant line
by counterelectrophoresis correlated with an antistreptoki-
nase antibody titer of greater than 150 IU/ml of serum. On
the basis of an estimated blood volume of 5 liters and an
hematocrit of 42%, our patient would have been capable of
neutralizing more than 1.5 million units of streptokinase.
Discussion
Previous studies of failure of streptokinase throm-
bolysis. Experimental and clinical studies have confirmed
the efficacy of streptokinase as a thrombolytic agent for the
treatment of acute myocardial infarction. Athough success-
ful reperfusion has been reported in up to 93% of patients
treated with streptokinase, the reasons for failure are usually
unclear (16). When streptokinase fails to achieve reperfu-
sion , it is important to determine whether activation of the
fibrinolytic system has occurred . Systemic administration
of streptokinase results in a marked decrease in serum plas-
minogen, the generation of circulating plasmin, a decrease
in serum fibrinogen and a marked increase in fibrin deg-
radation products. In vitro testing demonstrates increased
plasma fibrinolytic activity. These changes are independent
of whether or not thrombolysis is successful (17,18).
Failure to achieve thrombolysis and reperfusion after ac-
tivation of the fibrinolytic system by streptokinase may re-
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fleet inadequate dosage, low plasminogen concentration in
the thrombus, poor thrombus penetration by streptokinase
or the presence of an older more organized thrombus in
which the fibrin polymer is resistantto hydrolysis. The latter
suppositions are supported by the observations that in some
patients treated by intracoronary administration of strepto-
kinase, reperfusion was achieved only after mechanical dis-
ruption of the thrombus by a guide wire (2,3), and that a
delay between the onset of chest pain and the start of strep-
tokinase therapy lowersthe success rate for reperfusion (19).
Although circulating antiplasmin factors may inhibit
plasmin-mediated fibrinogenolysi s, they do not inhibit the
formation of the streptokinase-plasminogen activator com-
plex nor the activationof plasminogen by this complex (20).
It is unlikely that they inhibit thrombolysis, which is me-
diated by thrombus-bound and not circulating plasmin.
Therefore, in the presenceof increased antiplasmin activity,
systemic administration of streptokinase results ina decrease
in serum plasminogen and the generationof circulatingplas-
min; fibrinogenolysis is attenuated or inhibited but throrn-
bolysis may still occur.
Present patient. In our patient, streptokinase failed to
initiate the fibrinolytic cascade. Neither plasminogen nor
fibrinogen was consumedin contrast to the markeddecrease
in serum plasminogenand fibrinogen levels that accompany
the induction of the lytic state by intravenous streptokinase
in other patients. In our experience, patients who receive
750,OW IU or more of streptokinase demonstrated a de-
crease in serum plasminogen to levels less than I% of con-
trol and a decrease in serum fibrinogen to less than 50
mg/IOr) ml during the 6 hours after the infusion. A small
increase in fibrin degradation products, as notedin this case,
has been described (21) after acute myocardial infarction,
but this increase is much smaller than the marked increase
to levels in excess of 500 JLg/ml recorded after intravenous
streptokinase fibrinogenolysis. Estimation of euglobulin lysis
time was not performed in this case, but we believe the
failureof streptokinaseto producea lyticstate is established.
Our semiquantitative assay for antistreptokinase antibody
confi rmed that our patient would have been capable of neu-
tralizing in excess of 1.5 million lU of streptokinase. The
data suggest that our technique is both sensitive and specific
for detecting a moderate to high titer of antistreptokinase
antibody and, further, it is unlikely thatour technique would
identify a low titer because no precipitant line was observed
in any of the pretreatmentsera, even though in most of these
sera, a low titer of antistreptokinase antibody was probably
present.
An additional dose of streptokinase may have produced
reperfusion in this patient; however, more than 8 hours had
elapsed from the onset of chest pain before the mechanism
of failure had become apparent, too late to achieve signif-
icant myocardial salvage.
Our patienthad a positive antistreptolysin 0 screen with-
out a history of recent infection, Whether this screen can
identify the infrequent patient with a high antistreptokinase
antibody titer is not known because both the frequency of
a positive antistreptolysin 0 screen and its relation to the
antistreptokinase antibody titer in patients undergoing
thrombolytic therapy have not been investigated.
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